Who We Are

A Patient-centered Health Intelligence Company Advancing Healthcare Through Data-driven Insights

Sema4 is transforming healthcare by using artificial intelligence to enable the delivery of precision medicine as the standard of care.

Who We Are

A Patient-centered Health Intelligence Company Advancing Healthcare Through Data-driven Insights

Sema4 is transforming healthcare by using artificial intelligence to enable the delivery of precision medicine as the standard of care.

Centrellis®:
Our Health Data Engine

Our unique analytics platform, Centrellis, enables us to transform standard of care insights by reconstructing longitudinal patient journeys, derive population health insights, and deliver AI-powered disease models.

Robust
Research

Sema4’s accomplished research team includes world leaders in data science, machine learning, network modeling, and genomics. We’ve published more than 180 peer-reviewed papers and are committed to providing science-driven solutions to the most pressing medical needs.

Our areas of focus

Women’s Health

Our Sema4 Elements portfolio of information-driven genomic solutions, digital tools, and services enables providers to treat patients holistically during their reproductive and generational health journey, from preconception planning to hereditary cancer testing.

Hereditary Cancer

Our hereditary cancer testing can provide actionable insights to guide clinical care decisions and better prevent, detect, or treat certain cancers.

Biopharma

Sema4 offers an extensive portfolio of health information solutions, including pre-clinical and clinical trial support, analytics for actionable insights, and advanced sequencing services, to drive informed decision-making across the drug discovery, development, and commercialization lifecycle.

Latest News
November 14th, 2022

Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction

October 31st, 2022

Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies

October 27th, 2022

Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns

Featured In
CBS logoBloomberg logo
Awards & Recognition
Fast Company
List of the World’s
Most Innovative Companies
Forbes
List of America’s Best Startup Employers
Gartner
Cool Vendor in Healthcare Technology
CB Insights
Digital Health 150